Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma:A case report

作     者：Peng-Bo Deng Juan Jiang Cheng-Ping Hu Li-Ming Cao Min Li 

作者机构：Department of Respiratory MedicineNational Key Clinical SpecialtyBranch of National Clinical Research Center for Respiratory DiseasesXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Xiangya Lung Cancer CenterXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Center of Respiratory MedicineXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Clinical Research Center for Respiratory Diseases in Hunan ProvinceChangsha 410008Hunan ProvinceChina National Clinical Research Center for Geriatric DisordersXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第5期

页      面：1580-1585页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases(Lung Cancer) National Key R&D Program of China,No.2016YFC1303300 Xiangya Clinical Big Data Project of Central South University(Clinical big data project of lung cancer) 

主　　题：Cytokine release syndrome Non-small cell lung cancer Immune checkpoint inhibitors Nivolumab Tumor necrosis factorα Interleukin-1β Interleukin-6 Case report 

摘      要：BACKGROUND Cytokine release syndrome(CRS)is defined as systemic inflammation that usually occurs following chimeric antigen receptor T-cell therapy administration;however,it has not been reported in patients with untreated non-small cell lung cancer to *** SUMMARY A 44-year-old nonsmoking woman presented to the hospital due to fever,palpitation,nausea,and cough for 1 mo and was diagnosed with stage cT3N3M0(IIIc)adenocarcinoma of the *** examinations revealed elevated cytokine[tumor necrosis factor-α,interleukin(IL)-1β,and IL-6]and inflammatory factor levels,which decreased after treatment with corticosteroids and immunoglobulin and when tumor growth was controlled following chemotherapy,radiotherapy,and antiangiogenesis ***,tumor recurrence was *** administration of nivolumab as third-line treatment,the patient’s condition was transiently controlled;however,CRS-like symptoms suddenly emerged,which led to a resurgence of cytokines and inflammatory factors and rapid *** CRS can develop in treatment-naïve lung cancer *** with tumorrelated CRS may be at risk of CRS recurrence,aggravation,and onset of immune checkpoint inhibitor-related adverse events.